Currently, LMAT's 12-month EPS stands at $2.79, according to the most recent financial reports. During 2025, LMAT reported a per-share earnings of $2.55, which shows a rise compared to the EPS of $1.96 recorded in 2024. LMAT recorded an EPS of $0.66 for the quarterly period ending on Sep 30, 2026.
In 2025, Lemaitre Vascular's earnings per share was $2.55, a rise of 30.1% from $1.96 in 2024. Over the quarter ending Sep 30, 2026, the earnings per share came in at $0.66, reflecting a 14.3% decline compared to the same quarter a year earlier. As of September 2026, the TTM EPS is $2.79. During 2024, the annual earnings per share was $1.96, representing an increase of 44.1% compared to 2023.
Lemaitre Vascular has recorded a decline in earnings per share of 14.3% in the past 12 months (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 39.5% per year. Lemaitre Vascular had an average annual EPS growth of 19.4% in the last five years. When assessed over a ten-year period, LMAT's average EPS annual growth was 19.2%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| TFX Teleflex Incorporated | 18.42 | -1,462.4% | N/A | N/A |
| BSX Boston Scientific Corp | 18.59 | 55.6% | 63.3% | N/A |
| LMAT Lemaitre Vascular Inc | 27.86 | 30.1% | 39.5% | 19.4% |
| EW Edwards Lifesciences Corp | 59.6 | -73.6% | -9.2% | 6.9% |
| ANGO Angiodynamics Inc | N/A | -6% | N/A | N/A |
| BAX Baxter International Inc | N/A | -47.2% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.